HCPCS code J0850 – Cytomegalovirus immune globulin injection

Key takeaways

HCPCS code J0850 covers cytomegalovirus immune globulin intravenous (human) and is billed per vial, not per milligram or dose weight.

CytoGam is the drug billed under J0850, while general IVIG products carry their own codes, such as J1459, J1561 and J1568.

Medicare Part B pays J0850 at average sales price plus 6%, and Medicaid and many commercial payers require an 11-digit NDC on the claim.

Pabau, the practice management platform we build, stores each prior authorization as a case and flags claims that go out without one.

HCPCS code J0850: Official descriptor and drug overview

HCPCS code J0850 is the Level II drug code assigned to cytomegalovirus immune globulin intravenous (human), with a billing unit of per vial. The CMS HCPCS Level II code set designates J-codes for drugs that are not self-administered. A physician or qualified healthcare professional typically gives them in a clinical setting.

CytoGam, now marketed by Kamada, is the commercially available preparation billed under J0850. The drug is a purified human immunoglobulin G product with high CMV antibody titers, distinct from general-purpose IVIG formulations.

What J0850 covers and what it excludes

HCPCS code J0850 covers cytomegalovirus immune globulin intravenous (human) when administered for FDA-approved indications. The FDA labeling for CytoGam identifies prophylaxis of CMV disease in kidney, lung, liver, pancreas, and heart transplant recipients as the approved uses.

The list below separates the uses J0850 covers from the ones that bill under another code or need extra approval.

• Covered: CMV prophylaxis in solid organ transplant recipients (kidney, liver, lung, heart, pancreas) per FDA labeling
• Payer-dependent: CMV treatment in transplant recipients is off-label, so it is covered only where an LCD or payer policy supports it
• Not covered: Other IVIG products, which carry their own codes: Gamunex J1561, Privigen J1459 and Octagam J1568
• Not covered: Subcutaneous immune globulin formulations, which bill under different J-codes
• Not covered without prior authorization: Off-label use in non-transplant immunocompromised patients
• Not covered: CMV-IGIV billed as a self-administered drug under Part D

Documentation requirements for J0850 claims

Payers check a J0850 claim against the clinical record, because the drug is tied to transplant status. Document these elements before the claim goes out, as part of routine medical billing compliance, rather than during an appeal.

• Transplant type and date: The chart must state the organ transplanted and the procedure date, supporting ICD-10-CM Z94.x status codes
• CMV serostatus: Donor and recipient CMV serostatus results, particularly for high-risk (D+/R-) combinations that meet LCD criteria
• Ordering diagnosis: ICD-10-CM code for CMV disease (B25.x) or transplant status (Z94.0-Z94.9) documented by the treating physician
• Drug ordered and administered: Order for CytoGam by name, dose in grams or mg/kg, and confirmation of actual dose given
• Vial count: Number of vials opened and administered, because J0850 bills per vial
• Administration route and setting: IV infusion, site of service, infusion start and stop times for companion CPT codes
• NDC number: The 11-digit NDC from the CytoGam vial or carton administered

Billing units and dosage calculation for HCPCS code J0850

HCPCS code J0850 is billed per vial, not per milligram, gram, or dose weight. The CytoGam prescribing information doses in mg/kg, so the ordered dose has to be converted into a vial count using the vial size. Teams that know the wider medical billing workflow catch unit errors before payers return them as CO-16 denials.

CytoGam is supplied as a 50 mL vial containing 2,500 mg (2.5 g) of immune globulin. A patient weighing 70 kg prescribed 150 mg/kg receives 10,500 mg total. That requires five full vials (5 × 2,500 mg = 12,500 mg) to cover the dose. The claim reports 5 units of J0850.

Companion CPT administration codes to bill with J0850

The drug code J0850 covers only the drug itself. The infusion service requires a separate CPT administration code reported on the same claim when billing in the physician office or non-facility setting. The first hour of a CytoGam infusion goes on the claim as 96365, with 96366 added for each additional hour.

In the hospital outpatient setting (POS 22), the facility bills the administration CPT codes under OPPS. The physician’s professional claim typically does not separately bill infusion administration there. Confirm with your MAC billing articles for the applicable setting.

J0850 vs. other immune globulin J-codes: Choosing the right code

A claim that bills the wrong immune globulin code no longer matches the drug in the chart, and payers deny or recoup it. HCPCS code J0850 is specific to cytomegalovirus immune globulin intravenous (human). General IVIG products carry their own codes by brand and route, such as J1459 for Privigen and J1568 for Octagam. Check the AAPC Codify HCPCS lookup when a brand name you do not recognize appears on a drug order.

Medicare reimbursement for HCPCS code J0850: ASP pricing and coverage rules

Medicare Part B reimburses J0850 as a physician-administered drug at average sales price (ASP) plus 6%, per the CMS buy-and-bill reimbursement methodology. CMS updates the ASP payment limits every quarter. Check the current limit in the CMS ASP pricing files before billing each quarter. Medicare pays the lower of the billed charge and the payment limit, so a charge set from an old quarter’s file can leave money unpaid.

Reimbursement varies by setting. Non-facility (physician office, POS 11) and facility (hospital outpatient, POS 22) rates differ because facility overhead is captured separately under OPPS. In the hospital outpatient setting, J0850 may be subject to OPPS packaging rules, depending on the annual rulemaking threshold. Verify the current year’s packaging status with your MAC. Tracking each J0850 claim from submission to payment shows quickly when a quarterly rate change has left a claim short-paid.

Prior authorization requirements for J0850

Prior authorization requirements for HCPCS code J0850 vary by payer and plan year. No universal rule applies across commercial, Medicare, and Medicaid programs. Medicare fee-for-service generally does not require PA for J0850 when the indication matches LCD criteria, but Medicare Advantage plans impose their own PA requirements. Commercial plans frequently require PA, and Medicaid programs vary by state.

• Required clinical information for PA requests: Transplant type and date, CMV serostatus of donor and recipient, current immunosuppression regimen, ordered drug and dose, treatment duration
• Expected timelines: Urgent requests typically 24-72 hours; standard requests 3-5 business days (varies by payer)
• When PA expires mid-course: File a renewal request before expiration; bridging infusions administered after expiration without a renewed PA will deny as unauthorized service
• PA denial appeals: Request a peer-to-peer review with the medical director; provide the transplant program’s clinical protocol alongside FDA labeling for CytoGam

NDC reporting requirements when billing J0850

Medicaid and many commercial payers require an 11-digit National Drug Code (NDC) on claims for J0850. The NDC identifies the CytoGam product and package administered, in 5-4-2 format on the claim. Kamada’s current CytoGam listing is 49591-0532-51. An incorrect or missing NDC is a common cause of CO-16 denials.

• Format: 11 digits in 5-4-2 format; leading zeros must be added to reach 11 digits if the labeler, product, or package segment is shorter
• Unit of measure qualifier: Report “UN” (units) as the NDC unit qualifier for CytoGam, since billing is per vial
• NDC quantity: Must match the J0850 unit count on the claim line
• Where to find the active NDC: The vial label or the FDA’s National Drug Code Directory. NDCs can change with packaging updates, so verify against the vial administered rather than a stored code

Common J0850 claim denial reasons and how to fix them

J0850 denials usually trace back to one of five claim fields, shown below with the denial each one triggers. Pairing these checks with denial management in healthcare helps billing teams fix claims before submission rather than chasing appeals. For full code definitions, see the guide to denial codes in medical billing.

The table below gives the fix for each denial.

Place of service and setting considerations for J0850

Where the infusion occurs changes both the reimbursement rate and which administration codes are billable. Infusion centers and transplant programs administering CytoGam should confirm the correct place-of-service (POS) code with each encounter.

J0850 in transplant prophylaxis: Indication-specific billing tips

Transplant programs bill J0850 as a course of infusions rather than a single dose. That changes how diagnosis codes, authorizations and doses are documented across the course.

• Pair J0850 with the correct ICD-10-CM diagnosis codes: Report the Z94.x transplant status code, such as Z94.0 for kidney transplant status. Add a CMV diagnosis such as B25.9 when disease is present, or a prophylaxis-qualifying code when it is not
• Document the prophylaxis protocol: The chart should record the physician’s decision to use CMV-IGIV instead of, or alongside, antiviral prophylaxis. Reference the transplant type and CMV risk tier
• Repeat infusion courses: Each infusion in the course is billed as its own encounter, and the PA should cover the full planned course. Document the schedule (e.g., weeks 1, 2, 4, 6, 8 post-transplant) so payers can check claims against the protocol
• High-risk D+/R- recipients: These patients are the core prophylaxis group. Recheck the dose-to-vial calculation at each encounter, since body weight can change after transplant
• Secondary prophylaxis after CMV disease: If the patient develops active CMV disease (B25.x) and then receives secondary prophylaxis, document the transition in the chart. The diagnosis code shift between prophylaxis and treatment can affect LCD coverage

How Pabau keeps J0850 claims complete before submission

A J0850 claim draws on three sources: The infusion record, the payer portal holding the authorization, and the billing system. When those sit apart, a missing PA number or NDC only surfaces once the remittance comes back.

In Pabau, each claim is raised from the patient’s invoice and checked for missing or invalid details before it goes to your clearinghouse. Prior authorizations are stored as cases, and the code follows the appointment onto the claim. A claim with no authorization code is flagged before it leaves.

Pabau’s infusion practice claims software then tracks each claim from pending to paid and settles US payments from ERA files. Your team spends less time reworking CO-15 and CO-16 denials across a patient’s infusion course.

Stop J0850 claims from denying on avoidable errors

Pabau checks each claim for missing details before it reaches your clearinghouse and ties prior authorization codes to the appointment. Your J0850 claims go out complete.

Book a demo

Conclusion

J0850 pays reliably when the claim is assembled before the infusion, not after the denial. Confirm the authorization, the vial count and the current Kamada NDC while the order is still being scheduled.

The cost is a few minutes of checking per encounter. It is repaid on every repeat infusion in a transplant patient’s course, because the same clean claim template carries forward.

Book a demo to see how Pabau tracks prior authorizations and flags incomplete claims before they reach the payer.

Continue your research

Need to verify which denial codes are affecting your J0850 claims? Denial codes in medical billing covers the full CARC/RARC reference so you can map remittance denials to corrective actions.

Want a clearinghouse that handles specialty drug claim submissions? Medical claims clearinghouse guide explains how clearinghouses validate J-code claims before they reach the payer.

Looking to strengthen your broader billing compliance program? Medical billing compliance covers the documentation and audit-readiness steps practices need across all claim types.

Frequently asked questions